Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.60 |
| ▸ | CA4 | P22748 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4624747 | 0.98 | KDM4E (0.58) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL321766 | 0.90 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHMGB1NAPRT | |
| Phthalic Acid SCHEMBL2420682 | 0.86 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Formaldehyde SCHEMBL1582461 | 0.82 | KDM4E (0.47) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Catechol SCHEMBL15986788 | 0.82 | LMNA (0.55) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1829341 | 0.82 | ALDH1A1 (0.82) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL25288775 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL31332109 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL15568422 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL27871001 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030099724-A1 | Compounds for prevention of diabetic retinopathy | TURNER OLIVER E (US) | 2003-05-29 | — | — | US | claimed |
| US-20230211000-A1 | TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-11559580-B1 | Tissue-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210171589-A1 | TRUNCATED CARTILAGE-HOMING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-11013814-B2 | Cartilage-homing peptide conjugates and methods of use thereof | Blaze Bioscience, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200222549-A1 | RENAL-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2020-07-16 | — | — | US | disclosed |
| EP-3638290-A1 | RENAL-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200069812-A1 | CARTILAGE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2020-03-05 | — | — | US | disclosed |
| WO-2018232122-A1 | RENAL-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018170480-A1 | CARTILAGE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-7691788-B2 | Compositions and methods of using same in producing heavy oil and bitumen | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070295640-A1 | Compositions and Methods of Using Same in Producing Heavy Oil and Bitumen | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171589-A1 | TRUNCATED CARTILAGE-HOMING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE THEREOF | MATR3, CXCL12, UTRN | ALDH1A1 4576/4885KDM4E 4694/4885HPGD 3241/4885 |
| US-11331393-B2 | Renal-homing peptide conjugates and methods of use thereof | CXCL12, ATP6V1B1, VIP | ALDH1A1 3933/4885KDM4E 4786/4885HPGD 3045/4885 |
| US-20230211000-A1 | TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | CXCL12, CCL2, CD44 | ALDH1A1 3158/4885KDM4E 4784/4885HPGD 2387/4885 |
| US-11559580-B1 | Tissue-homing peptide conjugates and methods of use thereof | CXCL12, CCL2, CD44 | ALDH1A1 3158/4885KDM4E 4784/4885HPGD 2387/4885 |
| US-20200222549-A1 | RENAL-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | CXCL12, ATP6V1B1, SDF4 | ALDH1A1 4039/4885KDM4E 4785/4885HPGD 2555/4885 |
| US-11013814-B2 | Cartilage-homing peptide conjugates and methods of use thereof | CXCL12, CD44, CCL2 | ALDH1A1 3312/4885KDM4E 4715/4885HPGD 2524/4885 |
| US-20200069812-A1 | CARTILAGE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | CXCL12, CD44, CCL2 | ALDH1A1 3312/4885KDM4E 4715/4885HPGD 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.